Mind Medicine (MindMed) Inc. (MNMD)
After hours:
| Previous Close | 8.68 |
| Open | 8.64 |
| Bid | 8.65 x 500 |
| Ask | 8.71 x 400 |
| Day's Range | 8.26 - 8.72 |
| 52 Week Range | 2.41 - 12.22 |
| Volume | |
| Avg. Volume | 2,258,385 |
| Market Cap | 611.949M |
| Beta (5Y Monthly) | 2.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
MindMed to Present at Upcoming April Medical Conferences
NEW YORK, April 02, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences:
- Business Wire
MindMed Announces Voluntary Delisting from Cboe Canada
NEW YORK, April 01, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has elected to voluntarily delist its common shares from Cboe Canada, effective at the close of markets on April 10, 2024, and the notice of voluntary delisting has been accepted by Cboe Canada. MindMed’s common shares will continue to be liste
- Business Wire
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
NEW YORK, March 11, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will host one on one investor meetings at the Leerink Partners 2024 Global Biopharma Conference, which will be held in Miami, FL from March 11-13, 2024.
